 |
|
|
| |
To switch or not to switch: anticipating choices in biomedical HIV prevention - from Oral to Long Acting Injectable PrEP - 90 Men using PrEP Surveyed
|
| |
| |
Reported by Jules Levin
HIV Research for Prevention (HIVR4P), October 17-19, 2016, Chicago
Kathrine Meyers1, Yumeng Wu1, Sarit Golub2
1Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA;
2 Hunter College of the City University of New York, CUNY Graduate Center, New York, USA
REFERENCES
(1) ) Delany-Moretlwe S, Mullick S, Eakle R, Rees H: Planning for HIV preexposure prophylaxis introduction: lessons learned from contraception. Current opinion in HIV and AIDS 2016, 11(1):87-93.
(2) Krakower DS, Mayer KH: The role of healthcare providers in the roll out of preexposure prophylaxis. Current opinion in HIV and AIDS 2016, 11(1):41 48.
(3) Meyers K, Golub SA: Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities. Current opinion in HIV and AIDS 2015, 10(4):290-295.
(4) Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN: High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PloS one 2014, 9(12):e114700.
(5) Mera R, McCallister S, Palmer B, Mayer G, Magnuson D, Rawlings K: FTC/TDF (Truvada) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: 2013-2015. 21st International AIDS Conference, Durban, abstract TUAX0105LB, 2016.
|
| |
|
|
|
|
|
